These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24853213)

  • 1. Point/Counterpoint: early detection of prostate cancer: do the benefits outweigh the consequences?
    Carroll PR; Vickers AJ
    J Natl Compr Canc Netw; 2014 May; 12(5 Suppl):768-71. PubMed ID: 24853213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.
    Carter HB
    BJU Int; 2013 Sep; 112(5):543-7. PubMed ID: 23924423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen-based screening: controversy and guidelines.
    Kim EH; Andriole GL
    BMC Med; 2015 Mar; 13():61. PubMed ID: 25857320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016.
    Carroll PR; Parsons JK; Andriole G; Bahnson RR; Castle EP; Catalona WJ; Dahl DM; Davis JW; Epstein JI; Etzioni RB; Farrington T; Hemstreet GP; Kawachi MH; Kim S; Lange PH; Loughlin KR; Lowrance W; Maroni P; Mohler J; Morgan TM; Moses KA; Nadler RB; Poch M; Scales C; Shaneyfelt TM; Smaldone MC; Sonn G; Sprenkle P; Vickers AJ; Wake R; Shead DA; Freedman-Cass DA
    J Natl Compr Canc Netw; 2016 May; 14(5):509-19. PubMed ID: 27160230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection.
    Carroll PH; Mohler JL
    J Natl Compr Canc Netw; 2018 May; 16(5S):620-623. PubMed ID: 29784740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?
    Duffy MJ
    Ann Clin Biochem; 2011 Jul; 48(Pt 4):310-6. PubMed ID: 21525152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for prostate cancer: the current evidence and guidelines controversy.
    Gomella LG; Liu XS; Trabulsi EJ; Kelly WK; Myers R; Showalter T; Dicker A; Wender R
    Can J Urol; 2011 Oct; 18(5):5875-83. PubMed ID: 22018148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines.
    Carroll PR; Parsons JK; Andriole G; Bahnson RR; Barocas DA; Catalona WJ; Dahl DM; Davis JW; Epstein JI; Etzioni RB; Giri VN; Hemstreet GP; Kawachi MH; Lange PH; Loughlin KR; Lowrance W; Maroni P; Mohler J; Morgan TM; Nadler RB; Poch M; Scales C; Shanefelt TM; Vickers AJ; Wake R; Shead DA; Ho M;
    J Natl Compr Canc Netw; 2014 Sep; 12(9):1211-9; quiz 1219. PubMed ID: 25190691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen-based prostate cancer screening: Past and future.
    Alberts AR; Schoots IG; Roobol MJ
    Int J Urol; 2015 Jun; 22(6):524-32. PubMed ID: 25847604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen test for prostate cancer screening: American Society of Clinical Oncology provisional clinical opinion.
    Nam RK; Oliver TK; Vickers AJ; Thompson I; Kantoff PW; Parnes HL; Loblaw A; Roth BJ; Williams J; Temin S; Basch E
    J Oncol Pract; 2012 Sep; 8(5):315-7. PubMed ID: 23277770
    [No Abstract]   [Full Text] [Related]  

  • 11. The current state of prostate-specific antigen testing.
    Lewis R; Hornberger B
    JAAPA; 2016 Sep; 29(9):51-3. PubMed ID: 27575906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen screening in prostate cancer: perspectives on the evidence.
    Wilt TJ; Scardino PT; Carlsson SV; Basch E
    J Natl Cancer Inst; 2014 Mar; 106(3):dju010. PubMed ID: 24594482
    [No Abstract]   [Full Text] [Related]  

  • 13. Prostate cancer: measuring PSA.
    Pezaro C; Woo HH; Davis ID
    Intern Med J; 2014 May; 44(5):433-40. PubMed ID: 24816306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor biomarkers: PSA and beyond.
    Melichar B
    Clin Chem Lab Med; 2012 Nov; 50(11):1865-9. PubMed ID: 23072854
    [No Abstract]   [Full Text] [Related]  

  • 15. Early detection, PSA screening, and management of overdiagnosis.
    Borza T; Konijeti R; Kibel AS
    Hematol Oncol Clin North Am; 2013 Dec; 27(6):1091-110, vii. PubMed ID: 24188254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reevaluating PSA Testing Rates in the PLCO Trial.
    Shoag JE; Mittal S; Hu JC
    N Engl J Med; 2016 May; 374(18):1795-6. PubMed ID: 27144870
    [No Abstract]   [Full Text] [Related]  

  • 17. Screening for prostate cancer with PSA testing: current status and future directions.
    Croswell JM; Kramer BS; Crawford ED
    Oncology (Williston Park); 2011 May; 25(6):452-60, 463. PubMed ID: 21717898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PSA in screening for prostate cancer: more good than harm or more harm than good?
    Duffy MJ
    Adv Clin Chem; 2014; 66():1-23. PubMed ID: 25344984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Who and when should we screen for prostate cancer? Interviews with key opinion leaders.
    Carlsson S; Leapman M; Carroll P; Schröder F; Albertsen PC; Ilic D; Barry M; Frosch DL; Vickers A
    BMC Med; 2015 Nov; 13():288. PubMed ID: 26612204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012.
    Butler SS; Muralidhar V; Zhao SG; Sanford NN; Franco I; Fullerton ZH; Chavez J; D'Amico AV; Feng FY; Rebbeck TR; Nguyen PL; Mahal BA
    Cancer; 2020 Feb; 126(4):717-724. PubMed ID: 31794057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.